News
Sibel Health Receives EU MDR Class IIb CE Mark for ANNE" One: The First Wireless Wearable Patient Monitoring Platform Certified to Key Interoperability Standards
1+ hour, 26+ min ago (451+ words) Bio Space Sibel Health Receives EU MDR Class IIb CE Mark for ANNE" One: The First Wireless Wearable Patient Monitoring Platform Certified to Key Interoperability Standards Class IIb certification and SDC interoperability bring traditional patient-monitor to a wireless, wearable form…...
Sono Thera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines
1+ min ago (656+ words) Bio Space Sono Thera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - Financing was led by Vida Ventures, with participation from ARK Invest, Cure Duchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, Sym Biosis,…...
Sanofi cans late-stage study for rare autoimmune disease on underwhelming efficacy
7+ min ago (331+ words) Sanofi is pulling the plug on a late-stage study of its investigational complement inhibitor riliprubart in chronic inflammatory demyelinating polyneuropathy'a move that analysts say could have broader ramifications across the drug class. The decision to discontinue the trial, dubbed MOBILIZE,…...
Predicta Biosciences and CIMA LAB Diagnostics Announce Agreement to Advance Ultrasensitive Blood-Based Diagnostics for Multiple Myeloma and Other Hematological Malignancies
8+ min ago (191+ words) Led by Dr. Bruno Paiva, the CIMA LAB Diagnostics Flow Cytometry Unit has recognized expertise in the diagnosis and monitoring of hematologic malignancies. Flow cytometry is an essential technique for differential diagnosis, prognostic classification, and monitoring minimal residual disease (MRD)…...
Disc's FDA meeting sets "clear path' for embattled rare blood disease drug
32+ min ago (420+ words) Four months after its rare blood disorder drug was rejected by the FDA, Disc Medicine has reached an agreement with the agency to resubmit. The FDA will allow the use of Disc's current Phase 3 trial, dubbed APOLLO, to support another…...
Auragens Achieves AABB Accreditation, Marking Major Milestone in Regenerative Medicine Quality and Patient Safety
1+ hour, 5+ min ago (435+ words) Bio Space Auragens Achieves AABB Accreditation, Marking Major Milestone in Regenerative Medicine Quality and Patient Safety International regenerative medicine leader earns accreditation from one of the world's most respected organizations in cellular therapy, reinforcing its commitment to quality, traceability, and…...
Phore Most Announces Lead Oncology Programme and Appoints Chief Medical Officer to Support Clinical Entry
1+ hour, 10+ min ago (430+ words) Bio Space Phore Most Announces Lead Oncology Programme and Appoints Chief Medical Officer to Support Clinical Entry - Next-generation small molecule microtubule targeting agent, PMC-001, progressing towards Phase 1 - Comprehensive preclinical data package demonstrates differentiating oral activity and CNS penetration, unlocking treatment…...
Dana-Farber Cancer Institute Receives Historic $50 Million Yawkey Foundation Grant
9+ hour, 14+ min ago (282+ words) Transformational investment advances a 300-bed, next-generation facility designed to redefine cancer treatment and advance oncology research; the Jean and Tom Yawkey Bridge commemorates an eight-decade partnership that has helped shape the future of cancer research, patient care, and support The…...
Albert Einstein College of Medicine Launches BIO-VITAL to Accelerate Gerotherapeutics
9+ hour, 18+ min ago (477+ words) Bio Space Albert Einstein College of Medicine Launches BIO-VITAL to Accelerate Gerotherapeutics New Program Connects Biotech and Pharmaceutical Partners with Einstein's Aging Research Expertise and Scientific Infrastructure BRONX, N. Y. , June 9, 2026 /PRNewswire/ -- Albert Einstein College of Medicine has launched the Batia and…...
Critical Path Institute to Convene Drug Development Leaders at 2026 Global Impact Conference
9+ hour, 50+ min ago (70+ words) Annual conference returns to Washington, D. C. , Sept. 15-16; addresses challenges in establishing a new paradigm for how evidence of efficacy and safety is generated. The 2026 agenda spans: Additionally, on Thursday, Sept. 17, C-Path will convene a dedicated working session on C-Path's One to…...